Growing evidence suggests the pro-apoptotic effects of quinazoline-derived α-adrenoceptor antagonists against prostate cancer epithelial and endothelial cells, mechanistically via inducing apoptosis via activation of transforming growth factor (TGF)-β1 signaling, which controls EMT and differentiation, in diverse cell types,[47, 48], transcription of the NF-κB inhibitor IκBα, and engaging the death receptor Fas-associated death domain (FADD)-mediated caspase-8 activation,[47, 48]. This evidence concerns the gene TGFB1 and Familial prostate cancer.